SAGE THERAPEUTICS INC's ticker is SAGE and the CUSIP is 78667J108. A total of 260 filers reported holding SAGE THERAPEUTICS INC in Q2 2021. The put-call ratio across all filers is 2.05 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $22,754,251 | -54.7% | 1,105,513 | +3.6% | 0.00% | -50.0% |
| Q2 2023 | $50,195,981 | +15.0% | 1,067,545 | +2.6% | 0.01% | 0.0% |
| Q1 2023 | $43,648,694 | +113500.4% | 1,040,245 | +3.3% | 0.01% | +20.0% |
| Q4 2022 | $38,423 | -99.9% | 1,007,430 | +4.5% | 0.01% | -16.7% |
| Q3 2022 | $37,748,000 | +22.5% | 963,954 | +1.0% | 0.01% | +20.0% |
| Q2 2022 | $30,826,000 | +29.9% | 954,373 | +33.2% | 0.01% | +66.7% |
| Q1 2022 | $23,722,000 | -38.6% | 716,682 | -21.1% | 0.00% | -40.0% |
| Q4 2021 | $38,636,000 | -0.3% | 908,229 | +3.8% | 0.01% | 0.0% |
| Q3 2021 | $38,762,000 | -11.8% | 874,805 | +13.1% | 0.01% | -16.7% |
| Q2 2021 | $43,952,000 | -10.7% | 773,684 | +17.7% | 0.01% | -25.0% |
| Q1 2021 | $49,211,000 | -10.8% | 657,464 | +3.0% | 0.01% | -11.1% |
| Q4 2020 | $55,200,000 | +50.2% | 638,087 | +6.1% | 0.01% | +28.6% |
| Q3 2020 | $36,757,000 | +42.5% | 601,400 | -3.1% | 0.01% | +16.7% |
| Q2 2020 | $25,796,000 | +50.9% | 620,400 | +4.2% | 0.01% | +50.0% |
| Q1 2020 | $17,095,000 | -79.3% | 595,242 | -47.9% | 0.00% | -55.6% |
| Q4 2019 | $82,520,000 | +6.3% | 1,143,114 | +106.5% | 0.01% | -50.0% |
| Q3 2019 | $77,649,000 | -22.4% | 553,490 | +1.3% | 0.02% | -25.0% |
| Q2 2019 | $100,053,000 | +19.9% | 546,472 | +4.1% | 0.02% | +9.1% |
| Q1 2019 | $83,467,000 | -6.9% | 524,786 | -43.9% | 0.02% | +57.1% |
| Q4 2018 | $89,642,000 | +45.6% | 935,834 | +114.7% | 0.01% | -17.6% |
| Q3 2018 | $61,568,000 | -9.6% | 435,884 | +0.2% | 0.02% | -19.0% |
| Q2 2018 | $68,126,000 | -1.1% | 435,231 | +1.7% | 0.02% | -4.5% |
| Q1 2018 | $68,917,000 | +9.9% | 427,874 | +12.3% | 0.02% | +4.8% |
| Q4 2017 | $62,737,000 | +226.8% | 380,896 | +23.6% | 0.02% | +200.0% |
| Q3 2017 | $19,195,000 | -17.8% | 308,106 | +5.1% | 0.01% | -22.2% |
| Q2 2017 | $23,349,000 | +22.7% | 293,184 | +9.5% | 0.01% | +12.5% |
| Q1 2017 | $19,036,000 | +52.7% | 267,861 | +9.7% | 0.01% | +33.3% |
| Q4 2016 | $12,467,000 | +19.9% | 244,179 | +8.2% | 0.01% | +20.0% |
| Q3 2016 | $10,396,000 | +145.3% | 225,761 | +60.5% | 0.01% | +150.0% |
| Q2 2016 | $4,238,000 | +10.4% | 140,674 | +17.5% | 0.00% | 0.0% |
| Q1 2016 | $3,839,000 | -18.3% | 119,750 | +48.5% | 0.00% | -33.3% |
| Q4 2015 | $4,701,000 | +47.5% | 80,650 | +7.1% | 0.00% | +50.0% |
| Q3 2015 | $3,188,000 | -40.1% | 75,337 | +3.4% | 0.00% | -33.3% |
| Q2 2015 | $5,321,000 | +180.8% | 72,892 | +93.2% | 0.00% | +200.0% |
| Q1 2015 | $1,895,000 | +48.9% | 37,728 | +8.5% | 0.00% | 0.0% |
| Q4 2014 | $1,273,000 | +63.6% | 34,786 | +40.7% | 0.00% | 0.0% |
| Q3 2014 | $778,000 | – | 24,729 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Sio Capital Management, LLC | 179,200 | $29,516,000 | 16.65% |
| TRV GP II, LLC | 547,916 | $90,247,000 | 16.25% |
| Opus Point Partners Management, LLC | 71,000 | $11,694,000 | 10.12% |
| Casdin Capital, LLC | 250,000 | $41,178,000 | 10.03% |
| RA Capital Management | 455,173 | $74,972,000 | 6.27% |
| Crawford Lake Capital Management, LLC | 154,278 | $25,411,000 | 6.00% |
| Palo Alto Investors LP | 810,806 | $133,548,000 | 5.75% |
| GREAT POINT PARTNERS LLC | 200,000 | $32,942,000 | 5.62% |
| BB BIOTECH AG | 1,042,439 | $171,700,000 | 4.84% |
| Crawford Lake Capital Management, LLC | 92,300 | $15,203,000 | 3.59% |